Product Documentation

• View Summary of Product Characteristics (SmPC- Lenalidomide Accord 25 mg Hard Capsules)

  Last updated on this site: 07 Aug 2024

  1) To update section 4.4, 4.8 and 5.1 of SmPC in line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0126; MAH: Bristol Myers Squibb Pharma EEIG).

  2) To update sections 4.4 of SmPC and updating RMP in line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0123; MAH: Bristol Myers Squibb Pharma EEIG).

  View change history
• View Patient Information Leaflet (PIL- Lenalidomide Accord 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Hard Capsules)

  Last updated on this site: 27 Jun 2023

  Description of update:

  1) To update sections 4.2 and 4.4 of SmPC and section 2 of leaflet in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0122; MAH: Bristol Myers Squibb Pharma EEIG).

  2) To update section 5.1 of the SmPC in-line with the reference product (Revlimid; 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg Capsule, hard; EU procedure reference number: EMEA/H/C/000717/II/0124; MAH: Bristol Myers Squibb Pharma EEIG). Additionally, editorial updates have been made to sections 4.2, 4.4, 4.5, 4.8, 5.1 of SmPC and section 2, 3 and 4 of PIL in line with reference products.

  PIL sections updated: 2, 3, 6.

  View change history